Sanofi-Aventis's new chemotherapy drug Jevtana improves survival in advanced prostate cancer
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's investigational chemotherapy drug Jevtana (cabazitaxel) has improved median overall survival by over two months in the registrational Phase III TROPIC trial when tested as a second-line therapy in hormone-refractory prostate cancer (HRPC), a setting in which there is no standard therapy and few options.